The inhibitor has been approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen. OLYSIO works by blocking the viral protease enzyme that enables the hepatitis C virus to replicate in host cells.
More Articles on Supply Chain:
5 Ways Materials Management Information Systems Can Improve Surgery Center Supply Chain
Mazor Robotics’ Sells Renaissance Spine System to Lawnwood Regional Medical Center
Alphatec Spine Posts $14.5M Q3 Loss After PurGen Device Discontinuation
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
